AccessibilityHelpAbout Us

Biotest GmbH & KGaA(OTC) BIESF

Market Cap$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-33%
5 Year+44%
1 Year+0%
1 Month+0%
$31.91
+0.00%
+0.00Today
Biotest GmbH & KGaA last closing stock price
MetricPriceDate
Last closeUSD 31.952026-04-30
Biotest GmbH & KGaA stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 31.952026-02-09
1 month+0%USD 31.952026-02-09
3 month+0.15%USD 31.912025-03-10
Year to date+0.15%USD 31.912025-03-10
1 year+0.15%USD 31.912025-03-10
3 year-22.58%USD 41.272022-12-19
5 year+44.31%USD 22.142021-02-17
Since inception-33.33%USD 48.002010-02-12

Biotest GmbH & KGaA Financials at a Glance

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€635.20M

Net Income (TTM)

-€24.50M

EPS (TTM)

$0.00

P/E Ratio

-48.65

Dividend

$0.05

Beta (Volatility)

-0.02 (Low)

Price

$31.91

Volume

2

Open

$31.91

Previous Close

$31.91

Daily Range

$31.91 - $31.91

52-Week Range

$31.91 - $32.00

Estimated Earnings Date

Nov 10, 2025

BIESF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotest GmbH & KGaA

Biotest AG is a German biopharmaceutical company founded in 1946, specializing in advanced biological therapeutics. The company focuses on critical medical needs in hematology, clinical immunology, and intensive care medicine, offering a diverse range of products and services.

Products and Services
  • Innovative treatments for hemophilia, including Haemoctin and Haemonine
  • Immunotherapies for infections like Cytotect CP and Fovepta
  • Supportive therapies such as Albiomin and Trimodulin for various conditions
Growth Outlook
  • Recent quarterly revenue of €124.2 million indicates strong market demand
  • Operating income improved significantly to €52.8 million in Q1 2024
  • Positive cash flow from operations of €58.4 million in Q2 2024
Financial Highlights
  • Trailing twelve months (TTM) revenue of €1.1 billion reflects robust growth
  • Net income margin improved to 13.7% in Q1 2024
  • Current ratio of 5.06 suggests strong liquidity position
Biotest AG operates in a dynamic sector, focusing on innovative therapies that address significant medical needs. The company's recent financial performance demonstrates resilience and growth potential, with a strong emphasis on research and development. The diverse product portfolio positions Biotest well to capitalize on emerging opportunities in the biopharmaceutical market. Investors may find the company's commitment to innovation and its solid financial foundation appealing as it navigates the evolving healthcare landscape.
AI Generated • Sep 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,495

CEO

Peter Janssen, MBA

Website

www.biotest.de

Headquarters

Dreieich, 63303, DE

BIESF Financials

Key Financial Metrics (TTM)

Gross Margin

30.82%

Operating Margin

13.01%

Net Income Margin

3.64%

Return on Equity

5.13%

Return on Capital

-3.75%

Return on Assets

1.84%

Earnings Yield

-2.06%

Dividend Yield

0.14%

Payout Ratio

6.06%

Stock Overview

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

39.57M

Volume

2

Avg. Volume

0

Financials (TTM)

Gross Profit

€147.30M

Operating Income

€18.70M

EBITDA

€39.30M

Operating Cash Flow

€14.40M

Capital Expenditure

€0.00

Free Cash Flow

-€14.30M

Cash & ST Invst.

€41.80M

Total Debt

€668.70M

Biotest GmbH & KGaA Performance Analysis

Biotest GmbH & KGaA annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 542,407,845-11.0%
20232023-12-31EUR 740,131,74236.5%
20242024-12-31EUR 785,523,8276.1%
20252025-12-31EUR 732,334,232-6.8%
Biotest GmbH & KGaA sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-27.1%
Q32024-09-30-3.9%
Q42024-12-3135.0%
Q12025-03-31-39.0%
Biotest GmbH & KGaA annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.84-56.1%
20232023-12-31EUR 3.47N/A
20242024-12-31EUR 0.72-79.2%
20252025-12-31EUR -2.02N/A
Biotest GmbH & KGaA sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-67.6%
Q32024-09-30-204.2%
Q42024-12-3162.4%
Q12025-03-31-485.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

€124.20M

-42.3%

Gross Profit

€14.10M

-84.4%

Gross Margin

11.35%

N/A

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$507.53K

N/A

Employees

2,495

N/A

Net Income

-€21.40M

-172.5%

EBITDA

-€9.53M

-115.8%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

€41.80M

-57.7%

Total Debt

€668.70M

-3.5%

Accounts Receivable

€195.00M

N/A

Inventory

€523.70M

+19.4%

Long Term Debt

€639.80M

+49.0%

Short Term Debt

€28.90M

-89.0%

Return on Assets

1.84%

N/A

Return on Invested Capital

7.42%

N/A

Free Cash Flow

-€58.10M

-400.9%

Operating Cash Flow

-€58.10M

-400.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BITGFBiotage AB (publ)
$15.01+0.00%
TBGNFOxurion N.V.
$0.17+0.00%
MPSYFMorphoSys AG
$73.27+2.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About BIESF

What is the current price of Biotest GmbH & KGaA?

Biotest GmbH & KGaA is trading at $31.91 per share.

What is the 52-week range for Biotest GmbH & KGaA?

Over the past 52 weeks, Biotest GmbH & KGaA has traded between $31.91 and $32.00.

How much debt does Biotest GmbH & KGaA have?

As of the most recent reporting period, Biotest GmbH & KGaA reported total debt of €722.33M.

How much cash does Biotest GmbH & KGaA have on hand?

Biotest GmbH & KGaA reported €45.15M in cash and cash equivalents in its most recent financial results.

What is Biotest GmbH & KGaA’s dividend yield?

Biotest GmbH & KGaA currently has a dividend yield of 0.14%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services